Alto Neuroscience, Inc. Research and Development Expense
Alto Neuroscience, Inc. (ANRO) reported Research and Development Expense of $22.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Alto Neuroscience, Inc. research and development expense for the quarter ending 2026-06-30 was $22.11M, a 68.45% increase year-over-year.
- Alto Neuroscience, Inc. research and development expense for the quarter ending 2026-03-31 was $20.29M, a 103.47% increase year-over-year.
- Alto Neuroscience, Inc. research and development expense for the quarter ending 2025-12-31 was $12.00M, a 11.07% increase year-over-year.
- Alto Neuroscience, Inc. research and development expense for the quarter ending 2025-09-30 was $10.53M, a 19.41% decline year-over-year.
- Alto Neuroscience, Inc. research and development expense for fiscal 2025 was $45.62M, a 2.93% decline from fiscal 2024.
- Alto Neuroscience, Inc. research and development expense for fiscal 2024 was $47.00M, a 55.15% increase from fiscal 2023.
- Alto Neuroscience, Inc. research and development expense for fiscal 2023 was $30.29M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.11M 10-Q · filed 2026-08-12 | $42.40M 10-Q · filed 2026-08-12 | $54.40M derived: sum of 3 quarters · filed 2026-08-12 | $64.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $20.29M 10-Q · filed 2026-05-13 | $32.29M derived: sum of 2 quarters · filed 2026-05-13 | $42.81M derived: sum of 3 quarters · filed 2026-05-13 | $55.94M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $22.52M derived: sum of 2 quarters · filed 2026-03-16 | $35.65M derived: sum of 3 quarters · filed 2026-08-12 | $45.62M 10-K · filed 2026-03-16 |
| 2025-09-30 | $10.53M 10-Q · filed 2025-11-12 | $23.65M derived: sum of 2 quarters · filed 2026-08-12 | $33.62M 10-Q · filed 2025-11-12 | $44.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $13.12M 10-Q · filed 2026-08-12 | $23.10M 10-Q · filed 2026-08-12 | $33.90M derived: sum of 3 quarters · filed 2026-08-12 | $46.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.97M 10-Q · filed 2026-05-13 | $20.77M derived: sum of 2 quarters · filed 2026-05-13 | $33.83M derived: sum of 3 quarters · filed 2026-05-13 | $47.02M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $23.86M derived: sum of 2 quarters · filed 2026-03-16 | $37.04M derived: sum of 3 quarters · filed 2026-03-16 | $47.00M 10-K · filed 2026-03-16 |
| 2024-09-30 | $13.06M 10-Q · filed 2025-11-12 | $26.24M derived: sum of 2 quarters · filed 2025-11-12 | $36.20M 10-Q · filed 2025-11-12 | $45.84M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $13.18M 10-Q · filed 2025-08-13 | $23.14M 10-Q · filed 2025-08-13 | $32.78M derived: sum of 3 quarters · filed 2025-08-13 | $40.75M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $9.95M 10-Q · filed 2025-05-14 | $19.59M derived: sum of 2 quarters · filed 2025-05-14 | $27.56M derived: sum of 3 quarters · filed 2025-05-14 | $34.63M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $17.61M derived: sum of 2 quarters · filed 2025-03-20 | $24.68M derived: sum of 3 quarters · filed 2025-03-20 | $30.29M 10-K · filed 2025-03-20 |
| 2023-09-30 | $7.97M 10-Q · filed 2024-11-12 | $15.04M derived: sum of 2 quarters · filed 2024-11-12 | $20.65M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $7.07M 10-Q · filed 2024-08-13 | $12.68M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $5.61M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |